BONDRONAT

This brand name is authorized in Australia, Austria, Croatia, Ecuador, Estonia, France, Germany, Hong Kong SAR China, Ireland, Lithuania, Netherlands, Poland, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug BONDRONAT contains one active pharmaceutical ingredient (API):

1
UNII J12U072QL0 - IBANDRONATE SODIUM
 

Ibandronic acid belongs to the bisphosphonate group of compounds which act specifically on bone. Their selective action on bone tissue is based on the high affinity of bisphosphonates for bone mineral. Bisphosphonates act by inhibiting osteoclast activity, although the precise mechanism is still not clear. In vivo, ibandronic acid prevents experimentally-induced bone destruction caused by cessation of gonadal function, retinoids, tumours or tumour extracts.

 
Read more about Ibandronic acid

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 BONDRONAT Film-coated tablets MPI, EU: SmPC European Medicines Agency (EU)
 BONDRONAT Concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
M05BA06 Ibandronic acid M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BA Bisphosphonates
Discover more medicines within M05BA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
AU Pharmaceutical Benefits Scheme 5750P, 9357L, 9619G
DE Bundesinstitut für Arzneimittel und Medizinprodukte 00024213, 00283222, 03321176, 03323123, 03422635, 05891475, 05891481, 09384516, 09505227, 09620460, 09686192, 10385567, 10402550, 13916717, 15608776, 16160160, 16804338, 17936852
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 23.815-1-04-11
EE Ravimiamet 1173147, 1173158, 1173169, 1173170, 1173181, 1207987
ES Centro de información online de medicamentos de la AEMPS 96012009
FR Base de données publique des médicaments 61213881, 64530520
GB Medicines & Healthcare Products Regulatory Agency 109260, 75402, 75422
HK Department of Health Drug Office 42670, 52681, 52770, 61449
LT Valstybinė vaistų kontrolės tarnyba 1027764, 1027766, 1027767, 1027768, 1027769, 1027770
NL Z-Index G-Standaard, PRK 76945
PL Rejestru Produktów Leczniczych 100125388, 100125402, 100125419
SG Health Sciences Authority 11206P, 13425P
TR İlaç ve Tıbbi Cihaz Kurumu 8699543091815, 8699543091822, 8699543760032, 8699543760056
ZA Health Products Regulatory Authority 32/3.2/0114, A38/3.2/0381, A38/3.2/0562

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.